

INDEX

- Aceperone, 4, 16, 21, 26
Acetylcholine, 117, 124, 182, 221, 222
Acridan drugs, 157
Activity as a defense mechanism, 138
Adenosine triphosphatase (ATPase), 41
Adenylate cyclase, 47-49, 64, 73, 77, 182, 227
Adipsia, 94
Adrenergic receptor, beta-, 64
Adrenergic transmission, 203
Adrenochrome, 224
Adrenolytic activity, 25-26
Age, 174
Aggression, 113-119
 amphetamine-induced, 118
 apomorphine-induced, 113-119
 L-dopa-induced, 118
 isolation-induced, 118-119
 morphine withdrawal-induced, 117-118, 122
 pain-induced, 119
 shock-induced, 119
Agitation, 102-104
 and oxygen consumption, 102-104
AHR-2277, *see* Lemperone
Akinesia, 169
Alkaloid
 ergot, 60, 64, 79, 224
 rauwolfia, 207
Amantadine, 187
Amine
 biogenic, 207
 and reserpine, *see* Reserpine
 moiety, variation of, 9-14
 secondary amines, 9
 tertiary amines, 9-14
 secondary, 9
 tertiary, 9-14
 γ -Aminobutyric acid (GABA), 48, 182, 221, 225, 226
Amiperone, 4, 21, 26
Amnesia during psychosis, 222
Amphetamine, 72, 75, 76, 96, 99, 118, 119, 209
 and abnormal behavior, 123
 and aggression, 118
 antagonism, 15, 23, 26
 anti-, 96-105
 behavior, abnormal, 123
 intoxication, 179
 psychosis due to, 123
Anchor stimulus, 233
Animal, lesioned, starves to death, 94
Anisoperidone, 4, 7, 8, 21, 26
Anisoprolol, 4, 8, 22, 26
Anoxia, 180
Antiamphetamine action, 96-105
Anticholinergic drug, 113
Antipsychotic activity, 22-25
Antipsychotic medication, 46, 141, 230
 cost, 148-154
 maintenance treatment, 144-148
 new drugs, 155-160
 relapse rate, 144-148
 therapy, somatic, 152
Antischizophrenic drugs, *see* Schizophrenia
Anxiety (*see also* Pan-anxiety), 38
Aphagia, 94
Apomorphine, 46, 51, 53, 59, 70, 72-74, 77
 and aggression, 113-117
 antagonism, 15, 23, 27, 28
 and vomiting, 18, 66
Arecoline creates lucid intervals in schizophrenics, 222
Aryl group modification, 7-8
Assay, radioreceptor, 77-79
 measures neuroleptic levels in blood, 77-79
Astasia, 172

- Ataxia, 170
 ATPase, *see* Adenosine triphosphatase
 Atropine, 114, 233
 Avoidance behavior, 105-110
 shock-, 105
 Sidman, 23, 107
 Azaperone, 3, 4, 14, 21, 26, 66, 67
 Azaspiranyl butyrophenone, 8
- Baboon and fluphenazine, 186
 Baclofen, 190
 Benperidol, 3, 4, 8, 9, 13, 16, 18, 21, 23, 26,
 66-69, 104, 121
 Benztropine, 46, 107, 183
 Biogenic amine, *see* listings for individual
 compounds
 Biperiden, 186
 BOL, *see* Bromlysergic acid
 Brain
 damage, 172
 self-stimulation, 23, 110-113
 inhibition of, 111, 113
 Bromlysergic acid (BOL), 224
 2-Bromo- α -ergocryptine, 61
 Bromoperidol, 4, 9, 13, 21, 26, 66-69
 Buccal-lingual-masticatory syndrome, 165,
 171
 Bufotenin, 225
 (+)-Butaclamol, 46, 48, 51-55, 69
 Butaperazine, 142, 143
 γ -Butyrolactone, 45
 Butyrophenone, 1-35, 39, 47, 107, 124,
 137, 156
 activity and structure, 3-14
 discovery, 1
 modifications, 2, 7-14
 pharmacology, 25-31
 antipsychotic, 22-25
 duration, 17-21
 effectiveness, oral, 21-22
 potency, 17-21
 side effects, 25-29
 profiles in animals, 10
 structure, chemical, 2, 4-14
 and activity, 1-35
 Butyropipazone, 4, 14, 21, 26
 Butyrothionone, 7
- C 1-601, 4
 Caffeine, 204
 Carbonyl group modification, 8
 Cardiac failure, 209
- Carphenazine (*see also* Proketazone), 156
 Castration, 114
 Catalepsy, 15, 43, 96, 186
 and neuroleptic drugs, 186
 test, 15, 28
 Catecholamine, 47
 in brain, 119
 function, 207
 in urine, 224
Cebus appella, 186
 Centennial Symposium on Huntington's
 Chorea (1973), 182
 Chemoreceptor trigger zone, 31
 Chlordiazepoxide, 107
 Chloralhydrate, 107
 Chlorphenyl-GABA in schizophrenia, 226
 Chlorpromazine, 1, 2, 6, 9, 12, 13, 16-19,
 38-40, 106, 107, 110, 122, 124,
 129, 130, 136-144
 Chlorprothixene, 156
 Chlorprothixol, 156
 Chorea
 Huntington's, 182, 229
 involuntary movements, 183
 model, 231-232
 Sydenham's, 173
 Circling behavior, 104-105
 Clofluperol, 4, 12, 13, 22, 26
 Clomacran, 157
 Clonidine, 114
 Clopimozide, 5, 14, 16, 20, 21, 26
 active for several days, 111
 Clozapine, 44-46, 70, 72, 105, 159, 160,
 176, 188, 189, 227, 228
 weakest blocker of dopamine receptor,
 105
 Cocktail, lytic, 130
 Continuous performance test (CPT), 234
 CPT, *see* Continuous performance test
 CPZ, *see* Chlorpromazine
 Curve, dose-response
 for chlorpromazine, 141
 Cyclopropane, 8
 Cyproheptadine, 59, 60
- Deanol, 188
 Delay and Deniker introduce drug treatment
 for schizophrenia, 38
 Demethylation, 199
 Denervation, 182, 183
 Deniker and Delay introduce drug treatment
 for schizophrenia, 38
 Depression, symptoms of, 206
 Dextimide, 61

- Diarrhea due to reserpine, 205
 Diethazine, 226
 Diethylamide lysergic acid, 224
 3,4-Dihydroxyphenylamino-3-imidazoline, 68
 Diisopropylfluorophosphonate, 222
 3,4-Dimethoxyphenethylamine (DMPEA), 223
N,N-Dimethyltryptamine (DMT), 225
 Diphenylbutylpiperidine, 1-35
 activity and structure, 3-14
 discovery, 3
 pharmacology, 15-31
 antipsychotic, 22-25
 duration, 17-21
 effectiveness, oral, 21-22
 potency, 17-21
 side effect, 25-29
 profiles in animals, 10
 structure, chemical, 4-6, 14
 and activity, 1-35
 Disability, 179
 Disattention deficit, 233
 Disintegration, psychic
 recipitated by pan-anxiety, 38
 Disorder
 attentional in schizophrenia, 135, 232
 irreversible, 166
 neuroleptic-induced, 168
 reversible, 168
 DMPEA, *see* 3,4-Dimethoxyphenethylamine
 DMT, *see* *N,N*-Dimethyltryptamine
 L-Dopa, 114, 118, 123, 184, 185, 187, 204
 treatment for Parkinson's disease, 42, 184-185, 207
 Dopamine, 42-46, 59, 70, 117, 119, 181, 182, 203, 204, 221, 226-228
 and adenylyl cyclase, 47-49
 antipsychotic drug action, 141, 226
 on neuron, 46
 binding, 49, 50, 53, 54
 depletion, 203
 metabolism, 42-47
 and neuroleptics, 42-47
 pathway, 72, 94, 104
 receptor, 37-89, 167
 agonist, 45, 46, 52
 antagonist, 52
 antischizophrenic drug, binding of, 65-72
 binding, 54, 65-74
 and antischizophrenic drug, 65-72
 and chronic drug treatment, 74-77
 and supersensitivity, 72-74
 biochemical action of neuroleptic drug on, 37-89
 Dopamine (*cont'd*)
 receptor (*cont'd*)
 blockade, 30-31, 72, 79, 189
 by neuroleptic drugs, 30-31
 as a concept, 37-89
 hypersensitivity, 182
 labeling, 49-55
 and LSD, 57-65
 and neuroleptics, 37-89
 on the presynaptic dopamine terminal itself, 45
 supersensitivity, 74
 two-state model, 55-57
 types of, 63
 and schizophrenia, 123-124, 226
 synthesis, 46
 transmission in brain stem, 123
 turnover, 228
 Dopamine- β -hydroxylase, 224
 Drinking behavior, 93-94
 Droperidol, 3, 4, 9, 13, 16, 18, 22, 26, 66-72, 104, 157
 Drug, neuroleptic (*see also* listings for individual compounds), 37-89, 92, 96, 132-144, 147-148, 153-155
 acridan, 157
 antidopamine, 187
 antipsychotic, 133-144, 152, 155-160, 227
 efficacy, 133-144
 antischizophrenic, 48, 65-72, 74, 136, 222, 226
 blood level, 142-144
 combination, 153
 holiday, 147-148
 hunger, 122
 methodology of study, 132
 motor abnormality due to (*see also* Dyskinesia), 74, 165-195
 response, therapeutic, 14-16, 142-144
 treatment, 153-155
 aim, 139-153
 types, 175-176
 Dyskinesia, tardive, 74, 78, 147, 165-195
 clinical findings, 168-173
 classification, 168-169
 description, 169-173
 complications, 179
 diagnosis, differential, 174, 179-180
 disability, 179
 drug effects, 175-178
 current drugs, 83
 dosage, 175
 duration of treatment, 176
 intake, total, 175
 types, 175-176

- Dyskinesia, tardive (*cont'd*)
 factors
 age, 174
 diagnosis as, 174
 predisposing, 173-174
 sex, 174
 history, 165-167
 and L-dopa, 184-185
 models for, 182-186
 and neuroleptics, 167, 169, 175-177
 neuropharmacology, 181-186
 outcome, 177-178
 after continued drug therapy, 177-178
 after drug withdrawal, 177
 pathophysiology, 180-181
 reversible, 178
 in schizophrenia, 165-195
 symptoms, 178
 therapy, 186-188
- Dystonia, acute, 170, 173, 174
- Eating behavior, 93-94
- ECT, *see* Electroconvulsive therapy
- Effect of drugs, 175-178
 neurologic, induced by neuroleptics,
 listed, 169
- Electroconvulsive therapy for schizophrenia,
 152
- Encephalitis
 lethargic, 38
 viral, 169
- Encephalopathy, 168, 172, 173
- Ergocorbine, 61
- Ergocristine, 61
- α -Ergocryptine, 61
- Ergometrine, 61
- Ergot, 60, 64, 79, 224
- Ergotamine, 61
- Etonitazine, 117
- Ethopropazine, 226
- Extrapyramidal system, 181
- Fantasies, obsessive, 232
 preoccupation with, 232
- Feeding, 93-94
- Fenaperone, 14
- Fentanyl, 117
- Filtering defect of sensory impressions, 233
- Fluanisone, 3, 4, 8, 14, 22, 26, 66-69
- Fluorine, 7
- Flupenthixol, 48, 51-53, 55, 57, 66-69, 156
- Fluphenazine, 6, 16, 19, 22, 23, 26, 39, 40,
 48, 53, 56, 59, 66, 70, 72, 75, 76,
 133, 136, 138, 141, 171, 186
 depot, 152
 oral, 152
- Fluphenazine decanoate, 152
 enanthate, 143, 152
- Fluspirerone, 4, 9, 13, 18, 22, 26
- Fluspirilene, 5, 14, 15, 20, 26, 69, 157-159
- Fly-catcher's tongue, 168, 171
- Food-intake test, 23
- Frenolon, *see* Methophenazine
- GABA, *see* γ -Aminobutyric acid
- Hallucination, 222
- Haloperidone, 4, 22, 26
- Haloperidol, 3, 4, 8, 9, 12, 13, 16, 18-23,
 26, 28, 39, 40, 43-48, 53-55, 59,
 66, 70, 72, 75, 76, 94, 95, 104,
 111, 113, 114, 119, 121, 122, 124,
 176, 182, 186, 187, 226
 binding, 49-58, 65, 66, 71-77, 79
 discovery, 3
- Helix aspersa*, 64
- Heroin, 122
- Histamine, 182
- Homovanilic acid, 44, 104, 226, 228
- Hormone
 growth-, 232
 hypothalamic, 205
 pituitary, 205
- Hot-plate activity, measurement of, 2
- Huntington's disease (chorea), 180, 182, 229
 Centennial Symposium (1973), 182
 as model for tardive dyskinesia, 182-184
- HVA, *see* Homovanilic acid
- 7-Hydroxychlorpromazine, 79
- 6-Hydroxydopamine, 72, 73, 114, 182, 202
- 5-Hydroxytryptophan, 114
- Hypermotility, 183
- Hypersensitivity
 of dopaminergic receptors of lower
 neurons, 182
- Hypertension, control of, 207
- Hyperthermia, 170
- Hypophysectomy, 114
- Hypotensive action and reserpine, 201
- Hypothalamus, lateral
 and drinking behavior, 93
 and eating behavior, 93

- Hypothermia, 203, 204
 Hypotonia, 172
 Hysteriform condition, 38
- ID-4708, 4
 Indoleamine, transmethylation theory, 225
 Indoleamine *N*-methyltransferase, 225
 Insecticide, 222
 Insulin shock therapy for schizophrenia, 152
 Imipramine
 combined with chlorpromazine useless, 153
 Irritability, 222
 Isocarboxazide, 187
 Isoproterenol, 47, 51, 53
- Jumping box, 15, 23, 27
 Jumping, mouse, 99-102
 Jumping test, 15, 27
- Lateral hypothalamic syndrome recovery, 94-95
 Lemperone, 5, 26, 157
 Levodopa, *see* L-Dopa
 Lordosis, 172
 Loxapine, 156, 182
 Loxitane, *see* Loxapine
 LSD, *see* Lysergic acid diethylamide
 Lysergic acid diethylamide (LSD), 224
 brom-, 224
 and dopamine receptor, 57-65
 as mixed agonist-antagonist, 57-65
- Macaca mulatta*, 186
 Maintenance treatment with antipsychotic medication, 144-148
 relapse rate, 144-148
 Majeptil, *see* Thioproperazine
 Medication, antipsychotic, 144-154
 cost, 148-154
 depot, 152
 dispensing of, 20-26, 148-154
 preparing, 148
 time of staff required for, 148
 Mental institution as a true treatment center, 131
 Mepazine, 131, 137
 Meprobamate, 53, 107
 Mescaline psychosis
 as model for schizophrenia, 223
 Metaraminol, 208, 209
 Methadone, 117, 122
 Methionine loading
 exacerbates schizophrenia, 225
 Methiothepin, 59
 Methophenazine, 157
 Methoxytryptamine, 225
 3-Methoxytyramine, 43
 α -Methylnorepinephrine, 208
 Methylperidine, 22, 26
 Methylphenidate, 187, 222, 223, 226
 α -Methyl-*p*-tyrosine, 47, 75, 118, 182
 Methysergide, 59, 60
 Moban, *see* Molindone
 Molindone, 70, 155, 156
 Monoamine oxidase, 25, 127, 153, 209
 Moperone, 3, 5
 Morphine, 2, 117-118, 122
 Muscle tremor, 110
 Mydriasis, 2
 Myokymia, 171
- Naloxone, 114
 Narcotic withdrawal syndrome, 119-122
 Navane, *see* Thiothixene
 NE, *see* Norepinephrine
 Neuroleptics, 7, 37-89, 91-164
 action, behavioral, 91-128
 activity, 3, 30-31
 and aggression, 113-119
 and agitation, 102-104
 in animals, 92
 antiamphetamine action, 96-105
 antipsychotic action, 47
 assay, radioreceptor, 77-79
 avoidance behavior, 105-110
 and behavior, 91-128
 and brain self-stimulation, 110-113
 catalepsy, 96
 and circling behavior, 104-105
 and dopamine receptor, 37-89
 effects, comparative, 137-140
 efficacy, comparative, 134
 feeding behavior, 93-94
 and locomotor activity, 96
 and mouse jumping, 99-102
 and narcotic withdrawal syndrome, 119-122
 neurologic effects, listed, 169
 and oxygen consumption, 102-104
 in psychiatry, clinical, 129-164
 and schizophrenia, 37-89, 91

- stereotypy, 96-99
- structure, chemical, 29
- term proposed in 1955, 91
- Neurological disorders, 165-196
- Neuropharmacology, 181-186
- Neurotransmitter
 - and psychiatry, 228-232
 - receptor-binding, 49, 50
 - and schizophrenia, 221-242
 - theories, 221-242
- Nigrostriatal nerve tract, destruction of, 94, 95, 104
- Noradrenaline, 221, 223, 224
- Norepinephrine(NE), 26, 53, 119, 182, 203
 - antagonism, 15
- Normetanephrine, 43
- Norpethidine, 2

- Oculogyric crisis, 169
- Opisthotonus, 169
- Organophosphorus as insecticide, 222
- Overattentiveness, pathological
 - to one's surroundings, 233
- Oversedation, 26
- Oxygen consumption, 102-104
 - and agitation, 102-104
- Oxyperomide, 5, 22, 26, 114-117
- Oxypertine, 187

- Pan-anxiety and psychic disintegration, 38
- Paraldehyde, 107
- Parkinson's disease, 42, 74, 170, 173, 180, 184, 204, 229
 - L-dopa therapy for, 42, 207
- Penfluridol, 5, 14, 20, 21, 26, 69, 111, 157, 158
- Pentobarbital, 107
- Pentylentetrazol, 204
- Performance test, continuous, *see* Continuous performance test
- Pericyazine, 157
- Peridol, 2, 5, 12, 13, 22, 26
- Perphenazine, 6, 19, 22, 26, 107, 176
- Pethidine, 1
- Phencyclidine, 222, 233, 235
- Phenobarbital, 38
- Phenothiazine, 18, 38-41, 47, 102, 107, 133, 136, 140, 147, 152, 154, 155
 - antischizophrenic, 38, 235
 - high-dose treatment, 140-142
- Neuroleptics (*cont'd*)
 - profiles in animals, 10
 - in psychotherapy, 154
- Phenoxybenzamine, 114
- Physostigmine, 183, 188, 222, 233
- Pilocarpine, 115, 222
- Pimozide, 3, 6, 14, 16, 21, 26, 45, 48, 53, 66-70, 104, 111, 121, 157, 158
- Pinoxepin, 157
- Pipamperone, 3, 5
- Piperidine, 12
- Pipothiazine palmitate, 156
- Pituitary secretion, 205
- Placebo effect as a concept, 132
- Posturing, abnormal, 171
- Proketazine, *see* Carphenazine
- Prolactin, 223, 226, 228, 230
- Prolixin, *see* Fluphenazine
- Promazine, 40, 48, 53, 66-69, 72, 79, 137, 217
- Promethazine, 39, 43, 53, 75, 76
- Properyazine, 157
- Propranolol, 114, 224
- Propylene side chain, modification of, 8-9
- Propyperone, 5, 13, 14, 22, 26
- Protrusion of the tongue (*see also* Fly-catcher's tongue), 171
- Psilocin, 59
- Psychiatry, clinical
 - and neuroleptics, 129-164
- Psychosis, amnesia during, 222
- Ptosis, palpebral, 15, 26, 28
- Puffing of cheeks, 171
- Pyridoxine, 187

- Rauwolfia serpentina*, 197, 198
 - alkaloid, 207
 - root, 129
- α -Receptor antagonism, index of, 71
- Receptor action
 - two-state model of, 56, 58
- Reserpine acid, 199
- Reserpine, 1, 42, 75, 76, 114, 122, 176, 182, 197-219, 224, 226
 - and amine, biogenic, 207
 - analogs, 198, 199
 - binding, 208, 211, 212
 - biochemistry, 203-212
 - and biogenic amine, 207
 - and diarrhea, 205
 - distribution in body, 199-200
 - and dopamine depletion, 43
 - and other drugs, 209-210

- Reserpine (*cont'd*)
 history, 198-199
 metabolism, 199-200
 as neuroleptic, 202-203
 pharmacology
 clinical, 197-219
 in laboratory animals, 201-205
 receptor concept, 211-214
 and schizophrenia, 38, 206, 226
 and sleep, 206
 source of, 198-199
 Restlessness, 222
 Rhesus monkey, 186
 Risus sardonicus, 169
 Rotation, contralateral (*see also* Circling behavior), 77
- Saimira sciurea*, 186
 Scatchard plot, 54
 Schizophrenia, 37-89, 91, 124, 133-136, 174, 185, 223, 225
 acetylcholine theory, 222
 antischizophrenic drugs, 48, 65-72, 74, 136, 222, 226
 γ -aminobutyric acid theory, 225-226
 attention disorder, 232-235
 dopamine theory, 185, 226-228
 drug treatment introduced, 38
 dyskinesia, 165-190
 graveyard for neurophysiologists, 221
 insulin shock therapy, 152
 mescaline psychosis as a model, 223
 and methionine, 221
 and neuroleptics, 37-89, 91
 neurotransmitter theories, 221-242
 noradrenaline theory, 223-224
 paranoid, 69
 progressive disease, 185
 serotonin theory, 224-225
 symptoms, 135-136
 theories, biochemical, 123
 Schizophrenic patient, 130, 153
 "burned out," 141
 chronic, 175
 hospitalized reduced in numbers, 131
 and lesion, striatal, 231
 and neuroleptics, 37-89
 and reserpine, 38, 206, 226
 and response, bizarre, 135
 stereotypy, 180
 treatment, 152
 Scoliosis, 172
 Scopolamine, 107, 183, 233
- Seborrhea, 170
 Sedation, 26
 Seizure, 204
 Serotonin, 59, 119, 182, 202, 205, 207, 208, 221, 224-225
 Sex, 174
 Shock, electric, 105
 Sidman avoidance behavior, 23, 107
 SKF-10312, 156
 Sleep, 206
 Social therapy, 131, 154, 155
 Sodium valproate, 188
 Somatic therapy, 152
 Somnolence, 26
 Spasm
 of the mouth, 169
 of the neck, 169
 Speech impairment, 183
 Spiperone, 3, 5, 8, 9, 13, 16, 18, 22, 26
 Spiramide, 5, 8, 22, 26
 Spirilene, 5, 8, 22, 26
 Spiroperidol, 47, 48, 53, 66-69, 72
 Spiroxatrine, 5, 8, 22, 26
 Squirrel monkey, 186
 Stelazine, *see* Trifluoperazine
 Stereotypy, 96-99, 180
 amphetamine-induced, 231
 model, 231
 Sulpiride, 159
 Supersensitivity, 74
 Sydenham's chorea, 173
 Syringic acid, 199
 Syringoyl methylreserpate, 199
- Taractan, *see* Chlorprothixene
 Tardive dyskinesia, *see* Dyskinesia
 Tetanus, 169
 Tetrabenazine, 187, 188, 210
 Thiopropazate, 107
 Thioproperazine, 156
 Thioridazine, 44, 46, 69, 70, 107, 110, 133, 136, 154, 176, 227, 228
 Thiothixene, 51, 53, 57, 66-69
 Thioxanthene, 155
 derivatives, 137
 Thyrotoxicosis, 170, 180
Torpedo marmorata, 65
 Trabuton, 5, 8, 21, 26
 Tranquillization, 130
 first described in 1755, 198
 Transmitter, *see* Neurotransmitter
 Transport, active, 45
 Tremor, 170, 178

- Trifluoperazine, 6, 19, 22, 26, 48, 66-69,
72, 104, 107, 138, 141, 175, 176
- Trifluoperidol, 3, 5, 8, 12, 13, 26, 66-69,
104, 157
- Triflupromazine, 66-69
- Trihexyphenidyl, 107
- Trimethoxybenzoic acid, 199
- Trismus, 169
- Tryptamine, 225
- L-Tryptophan, 186, 187
 produces akinesia, 186
 produces rigidity, 186
- Tyramine, 209
- Tyrosine, 44
- Tyrosine hydroxylase, 45, 46, 47
- U-25927, 12
- Underattentiveness, pathological
 to one's surroundings, 233
- Vomiting, apomorphine-induced, 18, 66
- Von Economo's disease, 168, 184
- Withdrawal after drug, 119-122, 177
 and aggression, 117-118, 122
- Yohimbine, 224